Investor Presentaiton

Dato-DXd BEGONIA study interim data ESMO BC 2022 Highlights Daiichi-Sankyo Evidence of strong synergy between Dato-DXd and immune checkpoint inhibitor supports further development in TNBC Best change from baseline in target lesion size (%) 100- N=29 50- Anti-tumor activity Patients evaluable for 27 confirmed response³ Confirmed ORR, n (%) 20 (74) 95% CI 54-89 CR, n (%) 2 (7) PR, n (%) 18 (67) -50- I -100- PD-L1 expression (TAP 5% cutoff): High aHad the opportunity to have 2 postbaseline scans. Dotted lines indicate thresholds for partial response (-30%) and progressive disease (20%) *If the best percentage change from baseline of target lesions cannot be calculated due to progression, withdrawal, or death, the value is imputed at +20%. "." Patients with PD as best overall response. +CR with lymph node disease (CR per RECIST in lymph nodes, is <10mm) . Unconfirmed response. CR, complete response; ORR, objective response rate; PR, partial response, TNBC, triple negative breast cancer. Low Unknown/Missing t BEGONIA study Ph1b/2 study for TNBC 1L sponsored by AstraZeneca. Several drugs are tested for combination with durvalumab. ■Responses were observed regardless of PD-L1 expression, and confirmed ORR was 74% Combination of Dato-DXd + durvalumab demonstrated a safety profile which was consistent with known profile of the individual agents Part 1 is completed and enrollment of part 2 (expansion) is ongoing 24

View entire presentation